Most discussions about generative AI in life sciences start with the technology. Quality professionals should start somewhere else—with the record.

Our job has never been to produce documents. It has been to produce evidence that decisions were made correctly, by the right people, on the right information. Generative AI is only useful to us if it makes that evidence stronger. If it weakens it, it has no place in a GxP environment, however impressive the demo.

My career began in microbiology, and I spent years in quality assurance and auditing before moving into digital validation. From that seat, these are the five misconceptions I hear most often.

1. ‘Generative AI will replace quality and validation professionals.’

It will replace the drafting, not the judgment.

A large part of any validation team’s week goes into writing and reformatting protocols, trace matrices, summary reports, and responses to review comments. Generative AI can produce a solid first draft from approved templates, requirements, and historical packages in a fraction of the time.

What it can’t do, and shouldn’t do, is decide that a system is fit for its intended use. That decision, and the signature behind it, stays with a qualified person. The profession doesn’t shrink. It moves up, from author to reviewer and decision owner.

Put yourself in the shoes of an auditor reviewing training records. You see 50 SOPs marked read and understood by the same person in under an hour. Do you trust the accuracy of that training? Volume isn’t evidence. It never was, and speed will not make it so. The same test applies to anything generative AI produces: The question is not how fast it was created, but whether a qualified person actually engaged with it.

2. ‘If the model is good, the output can be trusted.’

In GxP, trust does not come from the model. It comes from context, traceability, and review.

An answer without sources is an opinion. An answer that shows which SOP, which deviation, or which change control it was built from is something a reviewer can verify. That’s the standard we already apply to people, and it’s the standard we should apply to AI.

This is also where the regulatory direction is clear. The U.S. Food and Drug Administration’s draft guidance on AI to support regulatory decision-making frames trust as a credibility assessment tied to a specific context of use. The draft EU GMP Annex 22 goes further for manufacturing and keeps generative AI out of critical applications, with a human in the loop for the rest. Different wording, same principle: The use case defines the level of rigor.

3. ‘The value is in breakthrough use cases.’

The first value is in the unglamorous work.

Faster first drafts. Shorter review cycles. Deviation and CAPA investigations that start with the full history already assembled instead of a week of searching. Gap assessments of procedures against a new regulation that take days, not months.

This is the move from efficiency to effectiveness. Once quality teams are no longer buried in routine documentation, they can spend their time on what actually reduces risk: better investigations, better root causes, earlier signals, and the continuous improvement that every quality system promises and few have the capacity to deliver.

4. ‘Generative AI is just automation, so validate it like automation.’

It is not, and treating it that way causes problems in both directions.

Classic computer system validation assumes a deterministic system: same input, same output, test it once, and control changes. Generative AI doesn’t behave like that. Trying to force it into a traditional script-based approach either blocks useful low-risk applications or gives false comfort on high-risk ones.

The answer is the risk-based thinking our industry already has in GAMP 5 and computer software assurance: Define the intended use; assess the effect on product quality, patient safety, and data integrity; and put the controls where the risk is. For most generative AI use cases today, the important control is simple: A qualified human reviews, decides, and signs, and the audit trail shows exactly what the AI contributed and what the human did with it.

5. ‘The companies with the most AI will win.’

Access to AI will be a commodity. Every company will have strong models.

The winners will be the organizations with governed knowledge, clear accountability, and an audit trail that can reconstruct any AI-assisted decision—in other words, the organizations with the strongest quality culture.

Data integrity taught us that it’s not enough to be right. You must be able to show how you got there. Generative AI doesn’t change that principle. It raises the stakes. I call it decision integrity: the ability to prove that a decision supported by AI was made on the right information, by an accountable person, under control.

Conclusion

Generative AI doesn’t lower the bar for quality. It gives quality teams a way to clear it more consistently, with more time for the judgment that only people can provide.

Organizations that treat regulation as a design brief, not a barrier, will be the ones that move from pilots to production first.